Latest early-stage breast cancer Stories
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein.
SAN FRANCISCO, Oct. 9 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens.
REDWOOD CITY, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc.
BEDFORD, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S.
ANAHEIM, Calif., July 27 /PRNewswire/ -- Xoft, Inc.
- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported that the St.
A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.
- Results of International Multi-Center Study Consistent with Suite of U.S. and European Clinical Studies Evaluating Oncotype DX - REDWOOD CITY, Calif. and KYOTO, Japan, April 20 /PRNewswire-FirstCall/ -- Genomic Health, Inc.
Most Recent Indication Expands Treatment Platform to Allow Axxent(R) System to Deliver Surface Brachytherapy, Including Intraoperative Radiation Therapy (IORT) SUNNYVALE, Calif., March 4 /PRNewswire/ -- Xoft, Inc., today announced that it has received clearance from the U.S.
- An armed gangster.